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Abstract 
 
Biocompatible polymer-coated nanoparticles are at the forefront of research into the ever 
expanding field of drug delivery. We synthesized a reactive O-imidazolide precursor of methoxy 
polyethylene glycol (MPEG) and linked it to poly-L-lysine of two separate molecular masses to 
synthesize biocompatible protected graft copolymers (MPEG-gPLL).  The synthesis of the 
reactive precursor was confirmed by NMR, and the synthesis of the protected graft copolymers 
was confirmed by HPLC and TNBS testing. MPEG-gPLLs were then used for coating gold 
nanoparticles obtained in the presence of citrate as a capping/reducing reagent. We also 
performed the assessment of stabilization using surface plasmon changes and fluorescence 
spectroscopy and determined the appropriate concentrations of PGC to be between 0.0156 and 
0.004 mg/ml and nanoparticles to be 0.99 mg/ml for optimal binding to the surface of the 
nanoparticles. 
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Introduction 
 
A challenge that the pharmaceutical industry has been facing since its inception is the 
ability to produce a form of drug that is fast acting, effective, and easily distributable.  Thus far, 
the industry has been dominated by medicines that are either orally dispensed or injected directly 
into the body.  The fundamental purpose of a medication is to deliver a concentrated dose of a 
pharmaceutical to a specific area of the body to both relieve symptoms and to treat the malady at 
hand; however, the aforementioned techniques of drug delivery haven’t been able to achieve the 
desired efficiency thus far (Vogelson, 2001).  Orally taken medications must be taken in higher 
than necessary doses due to their tendency to degrade en route to the area of responsibility, to 
treat continuously as opposed to when needed, and their likelihood of dissociating in areas of 
high pH or adverse tissue conditions (Vogelson, 2001).  For this reason, the pharmaceutical 
industry is turning to other methods, such as nanoparticles and polymer science, to be a key part 
of the future of drug delivery systems. 
Methoxy polyethylene glycol, or MPEG as it will henceforth be referred to, is an addition 
polymer synthesized from ethylene oxide and methanol.  Its general formula is given thusly, with 
n representing the number of oxyethylene monomer units present.   
 
Figure 1:  Structure of n-Methoxy Polyethylene Glycol 
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The presence of a terminal hydroxyl group gives MPEG the ability to undergo a number of 
modifications including carboxylation, tosylation, mesylation, and various other substitutions 
with the formation of a mono-functional activated derivative.  MPEG can be supplied in a variety 
of average molecular weights ranging from 350-5000 Da.  The molecular weight determines the 
phase of the polymer at room temperature; the procedures called for in this project use 5000 
weight MPEG, which presents as a white solid at RTP.   
 The properties and applications of MPEG derivatives have been studied at length, 
particularly those applications in the field of drug delivery (Vogelson, 2001).   The ability of 
MPEG to easily undergo substitution to gain functional groups as well as its ability of the 
resultant activated analogs to covalently modify amino, aldehyde and thio groups it a clear 
choice for attempts to create a delivery system for both covalently and non-covalently bonding 
drugs.  One primary focus is the creation of protected graft copolymers, or PGCs.   These highly 
versatile compounds consist of a conjugated backbone composed of polylysine and randomly 
distributed MPEG polymeric chains that provide multiple binding and linking sites (N- ε-amino 
groups of polylysine) for drugs and/or adaptors (Bullock, Chowdhury, Severdia, Sweeney, 
Johnston, and Pachla, 1997).  PGCs have historically been used as carrier molecules for use in 
MR imaging, but their biodegradability, non-toxic nature and abundance of positive charges at 
physiological pH are making them a popular choice for the delivery of drugs and DNA plasmids 
(Vogelson, 2001).  Biodegradability and non-toxicity ensure that the carrier system can last for a 
long time in physiological conditions without causing adverse effects to the patient, and the 
positive charges give PGCs the ability to form polyionic complexes with a variety of plasmids 
(Bogdanov and Mazzanti, 2012).  This makes PGCs a system of interest to the field of gene 
therapy. 
 9 
 
Background 
Modification of Methoxy Polyethylene Glycol 
  
Several different modifications of MPEG have provided a basis for the research and 
syntheses discussed in this project.  Methods for preparing tosylate, bromide, amine, and fatty 
acid ester derivatives have been established since the 1980’s and are constantly being 
reexamined to raise efficiency, produce higher yields, and form increasingly stable polymers 
(Harris and Yelpani, 1984).   
                                                    
Figure 2:  MPEG Derivatives (Tsui, 2009) 
 
The formation of MPEG-Imidazolide that is one of the focuses of this experiment 
employs a modified version of the previously accepted procedure for tosylation of MPEG.  
 10 
 
Previously, MPEG tosylation was accomplished by the addition of tosyl chloride to MPEG in a 
dichloromethane in the presence of pyridine (Harris and Yalpani, 1984).  However, this was 
found to result in an extensive level of polyethylene oxide chain cleavage, as well as forming a 
weakly reactive tosylate that was not able to be stored for longer periods of time without 
experiencing a gradual decomposition (1984).  Further research by Harris and Yalpani revealed 
that during mesylation and bromination, the procedure for tosylation benefited from the use of a 
60% excess of triethylamine as opposed to pyridine (1984).  MPEG tosylates are good starting 
compounds for synthesizing other derivatives because of the tosyl group’s ability to act as a 
leaving group while undergoing nucleophilic displacement.  Synthesizing MPEG tosylate 
enabled the further reaction with mercaptoacetic acid, producing a thioacetate that has been 
extensively researched at a later time as a precursor for MPEG-thiol, a single-chain stabilizer of 
gold nanoparticles.   
Instead of using tosylation or mesylation we investigated an alternative activated 
precursor for PEGylation, i.e.  MPEG-O-imidazolide which has been  previously suggested as a 
non-toxic, weakly reactive analog of MPEG that has been used for covalent modification of 
many proteins carrying primary amino groups. It was found that a procedure based upon the 
addition of 1,1’-carbonyl diimidazole (CDI) to MPEG could produce a relatively hydrolysis 
resistant, stable MPEG Imidazolide that is still sufficiently reactive in the presence of primary 
amino groups in the presence of water, especially if the nucleophilicity of amines is increased by 
using high pH. After the activation in the presence of CDI, the imidazolide is easily purified by 
hydrolyzing the excess of CDI and removing imidazole by water washes. The final purification 
can be easily performed, if required, by precipitating with a mixture of ethyl acetate and diethyl 
ether due to a lack of solubility of MPEG in diethyl ether and ethyl acetate.  All these reactions 
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were found to be most effective when done in a closed system under argon with completely 
anhydrous solvents and reagents, as MPEG on its own can suffer from oxidative complications 
from air and is highly soluble in water.   
  
Protected Graft Co-Polymers 
   
Synthesis of protected graft co-polymers is chiefly accomplished through the covalent 
grafting of modified MPEG chains to a polyamino acid.  A number of syntheses exist that yield 
the protected graft copolymer, but these are all highly dependent on the functional groups of the 
amino acids and the level of reactivity of the modified MPEG used (Bogdanov and Mazzanti, 
2012).  Research has shown that it is also possible to synthesize PGCs through the use of a 
polycarboxylic acid as opposed to a polyamino acid, but not all polymers of this nature are both 
biocompatible and biodegradable.  The synthesis performed by our laboratory was done using 
poly-L-Lysine and MPEG Imidazolide in alkaline environment, as past research has shown that 
poly-L-lysine achieves the highest degree of modification at a pH of 9.5 (Beauchamp, Gonias, 
Menapace, and Pizzo, 1983). The resultant polymer can be tested for remaining free amine 
groups; these groups can be further modified by using other amine-reactive compounds 
producing polymers with several types of molecules linked to a single amino acid backbone.  
 The presence of free amine groups on the poly-L-lysine backbone is an indicator of the 
completeness and the level of modification achieved in the PGC synthesis.  Our laboratory used 
the 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS) which is convenient to use in the case of water-
soluble macromolecules.  TNBS testing accomplishes this by mixing the amino-containing 
component (e.g. PGC) with 2,4,6-Trinitrobenzene Sulfonic Acid, a detergent, and water 
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(Schalkhammer, 2002).  The reaction between 2.4.6-Trinitrobenzene Sulfonic Acid and each free 
amine group results in a chromogenic derivative that can be analyzed qualitatively through a 
differences in absorbance values measured in the range 330-430 nm between the modified PGC 
and pure poly-L-lysine (2002).  
 
Figure 3:  Reaction Scheme for Trinitrobenzene Sulfonic Acid Test (Schalkhammer, 2002) 
 
An assay of modified PGC can be run simultaneously with a batch of pure poly-L-lysine and 
should show a decrease in absorbance due to the decrease in free amine groups associated with 
the successful synthesis of a PGC (2002).   Alternatively, our laboratory also used High 
Performance Liquid Chromatography (HPLC) to confirm synthesis.  The comparison of our 
products’ spectra with a general reference elution profile of the modified poly-L-lysine was used 
as an additional proof of an acceptable degree of modification.   
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Table 1:  Characterization of GNPs Showing Scattering Intensity Hydrodynamic Diameter (nm), Plasmon 
Intensity and Plasmon Peak Maxima (Bogdanov and Gupta, in preparation) 
Nanoparticle Synthesis and Modification 
  
Nanomaterials have been a primary focus in the field of drug delivery for the last decade 
based on their ability to increase longevity, solubility, and accumulation in target areas.  The 
particular focus on gold nanoparticles (GNPs) was based on a variety of factors, including past 
history of human use in anti-arthritis formulations,  not least of which is the ease with which they 
can be used for a plurality of novel applications, including bioelectronics and sensor 
development.  The uniqueness of gold nanoparticles is in the presence of strong surface Plasmon 
effect that results in very efficient excitation of surface Plasmon-polariton wave in the visible 
range of light, suggesting the applicability of GNPs in imaging. Research by Li and Guo 
suggests that gold engenders a stable environment for synthesis, as well as offering controlled 
degradation in physiological conditions and a chance for resonance imaging (Li and Guo, 2011).  
Coating these nanoparticles in polymers, or theoretically our PGC, should ensure 
biocompatibility and a “biological stealthiness” (2011).  GNPs covered in a layer of polymer 
Z-average hydrodynamic diameter; absorbance at λmax; λmax peak position. 
1 2 3 4 
159 nm; 0.232; 
530 nm 
122 nm; 0.336; 
530 nm 
108 nm;  0.523;  
535 nm 
116 nm;  0.616; 
535 nm 
149 nm;  0.261; 
530 nm 
109 nm;  0.372 
535 nm 
76 nm;  0.560 
535 nm 
43 nm;  0.672 
535 nm 
34 nm;  0.292; 
530 nm 
52 nm;  0.385 
535 nm 
49 nm;  0.593 
535 nm 
43 nm;  0.756 
535 nm 
33 nm;  0.303; 
530 nm 
35 nm;  0.437 
535 nm 
36 nm; 0.653;  
535 nm 
41 nm;  0.760 
535 nm 
40 nm;  0.281; 
530 nm 
37 nm; 0.398 
535 nm 
39 nm;  0.561 
535 nm 
41 nm;  0.608 
540 nm 
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offer an opportunity to carry a variety of functional groups, such as contrast agents and tissue 
specific ligands (2011).  Purification of these nanoparticles, once modified, can be accomplished 
by size-specific columns that utilize fiber filters with pores of a diameter that exclude the bulky 
nanoparticles and employ a centrifuge to move out all other solvents and reagents associated 
with synthesis.   
 The stability of PGC-coated GNPs is shown through their exposure to several different 
physiological conditions.  In order to ensure their appropriateness as a drug delivery system, their 
ability to aggregate must be confirmed; this is accomplished through a battery of tests simulating 
saline levels, phosphate levels, and its ability to aggregate in serum.  By again utilizing UV/Vis 
absorbance spectroscopy, we investigated the relative absorbance over time in order to ascertain 
the ability of the system to aggregate and stay stabilized in near-physiological conditions. 
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Methodology 
Drying Polythylene Glycol 
 
a. 50g of polyethylene glycol and 200 mL of >99.5% toluene were added to a 1 liter 
flask, stirred, and heated to 170 °C.  The mixture was then slowly heated to 180°C 
until 180 mL of distillate were collected.  The flask was cooled to room 
temperature, and a few milliliters of distillate were subsequently collected.  The 
reaction flask was then sealed and stored in a freezer.  This procedure was 
repeated twice more to ensure complete drying of the MPEG for subsequent 
syntheses. 
 
 Synthesis of MPEG Imidazolide 
 
b. 8.8 g of dried MPEG 5000 were dissolved in 45 mL of dried toluene and stirred 
under moderate heat to encourage dissolution.  139g of carbonyldiimidazole were 
dissolved in 20.5 mL of dioxane.  This was immediately added to the MPEG 
solution, which remained colorless.  This solution was placed over heat of 50°C 
with stirring.  The flask was flushed with argon, sealed, and allowed to sit 
overnight stirring with constant heat.  This solution was rotary evaporated at 60°C 
until a viscous yellow liquid remained.  100 mL of dichloromethane was added 
and the flask was placed in an ice bath, where the solution once again became 
colorless.  30 mL of 1 M sodium chloride was added; the flask was removed from 
the ice bath, and then stirred.  Stirring produced effervescence, so the solution was 
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stirred until evolution of bubbles ceased.  At this point, the solution split into a 
bilayer, with a colorless organic layer on bottom and a cloudy aqueous layer on 
top.  This was separated using a separatory funnel, washed with 30 mL of water 
and reseparated.  The clean organic layer was placed in another flask, where 
additional dichloromethane and andhydrous sodium sulfate were added and left 
over night.  The solution was once more rotary evaporated at 60°C, and the 
product was lyophilized and stored for later use. 
 
                                     
 
                              Figure 4:  Reaction of MPEG 5000 with Carbonyldiimidazole 
 
  Synthesis of MPEG Tosylate 
 
c. 8.06g of MPEG in 150 mL of toluene was rotary evaporated to dryness over the 
course of 20 minutes, resulting in a white crystalline product.  30 mL of dry 
dichloromethane was added to the flask and stirred until all crystals had dissolved.  
A septum was placed on the flask and the flask was flushed with argon.  2 mL of 
dry triethylamine were added.  A solution of 40 mL of dry dichloromethane and 
1.4g tosyl chloride was made during redissolution.  This mixture was added 
dropwise through the septum, after which the mixture turned a light yellow in 
color and was allowed to stir for 48 hours at RTP.  The light yellow mixture was 
then rotary evaporated until only a white solid remained.  This solid was 
Under Ar 
     → 
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redissolved in 30 mL of dichloromethane, then added to 175 mL of diethyl ether.  
Recrystallization began immediately, yielding a white crystalline solid.  This was 
allowed to precipitate at RTP overnight, then precipitated in a freezer over the 
course of 48 hours.  White crystals were vacuum filtered out of the mixture and 
washed with diethyl ether.  After completely drying, the crystals were redissolved 
in 25 mL of dichloromethane, forming a cloudy yellow mixture, then added to 
175 mL of diethyl ether.  This was allowed to precipitate briefly at room 
temperature, then precipitated in a freezer overnight.  The product was washed 
once more with dichloromethane and diethyl ether, then lyophilized and stored for 
later use. 
   Synthesis of MPEG Thioacetate 
 
d. 2g of MPEG tosylate were solubilized in 7.5 mL of dry dioxane and heated to 
55°C until solubilized completely.  This was filtered through 1 cm of celite by 
vacuum and transferred to a 50 mL flask that was then stoppered and flushed with 
argon.  0.25 mL of mercaptoacetic acid and 0.3 mL of pyridine were added.  The 
mixture remained colorless, was flushed with argon, and allowed to mix at RTP 
for 48 hours.  The mixture was once again vacuum filtered through 1 cm of celite 
and collected in an Erlenmeyer flask.  The filtrate was added drop-wise to a 
mixture of 30 mL of diethyl ether and 10 mL of ethyl acetate and mixed for 30 
minutes.  The product was a white crystalline solid that was vacuum filtered with 
a glass filter and washed with diethyl ether. 
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 First Synthesis of MPEG Imidazolide-Poly-L-Lysine PGC 
 
e. The following procedure was followed for both High Molecular Weight and Low 
Molecular Weight Poly-L-Lysine.  50mg of PLL hydrobromide were added to 
10mL of triethylammonium acetate buffer and adjusted to pH 9.5.  40 µl were 
removed for zero time point control.  PLL solutions were cooled on ice for 30 
minutes.  265mg of MPEG Imidazolide were added in three equivalent portions to 
the PLL solutions and vortex mixed.  pH was adjusted back to 9.5 using the 
triethylammonium acetate buffer.  The samples were prepared for TNBS testing 
as shown in Table 1.  All samples were vortexed before the addition of 2mM 
trinitrobenzene sulfonic acid, then incubated for 30 minutes.  Absorbance of 
samples was then measured to ensure modification had occurred. 
 
Tube Number 
Reagent 1 2 3 4 5 6 
Sodium 
Tetraborate 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
1% Triton X-100 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
Deionized Water 97 µl 97 µl 97 µl 97 µl 100 µl 800 µl 
MPEGI-PLL PGC 3 µl 3 µl 0 µl 0 µl 0 µl 0 µl 
PLL 0 µl 0 µl 3 µl 3 µl 0 µl 0 µl 
2 mM TNBS 700 µl 700 µl 700 µl 700 µl 700 µl 0 µl 
 
Table 1:   Test Tube Content Scheme for TNBS Testing 
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Figure 5:  A scheme of MPEG-Imidazolide synthesis and its reaction with pentalysine (illustrating a     
fragment  Poly-L-Lysine) 
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Second Synthesis of MPEG Imidazolide-Poly-L-Lysine PGC 
 
f. The following procedure was only used for High Molecular Weight Poly-L-
Lysine.  100mg of PLL hydrobromide was added to 20mL of triethylammonium 
acetate buffer and adjusted to pH 9.5.  80 µl were removed for zero time point 
control.  PLL solutions were cooled on ice for 30 minutes.  530mg of MPEG 
Imidazolide were added in three equivalent portions to the PLL solutions and 
vortex mixed.  pH was adjusted back to 9.5 using the triethylammonium acetate 
buffer.  The samples were prepared for TNBS testing using the same procedure 
described in Methodology Part E, except the Triton X-100 detergent was changed 
to a different detergent.  Samples were incubated for 30 minutes, vortex mixed, 
and absorbance was measured. 
 
 
 Third Synthesis of MPEG Imidazolide-Poly-L-Lysine PGC 
 
g. The following procedure was only used for High Molecular Weight Poly-L-
Lysine.  100 mg of PLL hydrobromide was added to 20mL of sodium borate 
buffer and adjusted to pH 9.5.  80 µl were removed for zero time point control.  
PLL solutions were cooled on ice for 30 minutes.  795mg of MPEG Imidazolide 
were added in three equivalent portions to the PLL solutions and vortex mixed 
after the addition of each portion.  pH was adjusted back to 9.5 using the sodium 
borate buffer.  The samples were prepared for TNBS testing using the same 
procedure described in Methodology Part E.  Absorbance was measured. 
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 Verification of Modification Using HPLC 
 
h. 50 µl of each synthesized MPEG Imidazolide-Poly-L-Lysine PGC were added to 
50 µl of sodium bicarbonate and 3 µl of 680 NHS radiolabeled dye.  This 
produced a blue colored solution that was allowed to sit for 30 minutes at RTP.  
15 µl of NHS ester of acetic acid were added to each sample and allowed to 
incubate at RTP for a further 30 minutes.  These samples were then run through 
P30 samples with 0.1 M Ammonium Acetate by spinning in a centrifuge for 4 
minutes at 1000 rcf three times.  These purified samples were run through a High 
Performance Liquid Chromatograph that served as a second verification of 
modification level of the poly-L-Lysine backbone.   
 Synthesis and Stabilization of MPEGI/PLL coated Gold Nanoparticles 
 
i. This procedure was used for the Low Molecular Weight PGC synthesized in 
Methodology Part E and the High Molecular Weight PGC synthesized in 
Methodology Part G.  10 µl of HAuCl4 were added to 10 µl of water.  These were 
heated to 95°C, then 1.75mL of 1% citrate solution were added to the solution.  
25mg of MPEGI-PLL were dissolved in 500 µl of water, then added to the GNP 
solutions.  These gradually changed from a light yellow solution to a reddish 
purple solution in the case of Modified MPEGI-PLL samples.  GNPs were also 
coated in pure poly-L-lysine using a similar procedure, and produced a reddish 
pink solution.  These were stored in a refrigerator for later stabilization testing. 
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   →                           
 
Figure 6:  Reaction of MPEGI/PLL with GNP 
                                                                                                
Stabilization Testing of MPEGI/PLL GNPs 
 
j.   Serial dilutions of MPEG-gPLL from 4mg/ml to 0.01 mg/ml were prepared in a 
well plate in volumes of 50 µl.  These were added to 200 mcl of citrate stabilized 
GNPs using a multi-channel pipette and allowed to incubate for 30 minutes.  
Absorbance was measured by absorbance spectroscopy reading from 500nm to 
550nm.  The plasmon peak shift that was observed was used to determine the 
MPEG-gPLL concentrations necessary for fluorescence spectroscopy.  Two rows 
of a well plate were prepared with concentrations of MPEG-gPLL-AF488 at 
0.156 and 0.04 mg/ml, and 90mcl of water was added to one well as a 100% 
polymer control well.  Citrate stabilized GNPs were diluted serially and 90 mcl of 
each well were added to the polymer wells using a multi-channel pipette.  After 1 
hour of incubation, this plate was tested for fluorescence intensity by exciting at 
490 nm and measuring emission at 520 nm. 
 
+
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Results and Discussion 
 
Confirmation of Syntheses 
 
 The first phase of this project was concerned with the successful synthesis of MPEG 
derivatives and their purification.  First, synthesis of MPEG-Imidazolide was attempted twice, 
with success confirmed by the use of a 300 MHz Bruker Nuclear Magnetic Resonance 
Spectrometer as shown below to collect proton NMR spectra.  The peaks observed on these 
spectra were consistent with the literature values for protons found in an Imidazolide. 
 
                     Figure 7:  NMR Spectrum of MPEG-Imidazolide Sample 1 
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                               Figure 8:  NMR Spectrum of MPEG-Imidazolide Sample 2 
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The further synthesis of an MPEG-Thioacetate was also confirmed using the same 
NMR.  The spectra shown below are also consistent with literature for formation of 
thioacetates.   
 
 
 
         
                                  Figure 9:  NMR Spectrum of MPEG-Thioacetate Sample 1 
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                                   Figure 10:  NMR Spectrum of MPEG-Thioacetate Sample 2 
 
 The next phase of the project, the synthesis of the protected graft co-polymers, was 
confirmed using TNBS testing and HPLC.  The results of TNBS testing are shown in the tables 
below.  Although the TNBS testing showed definite changes in the level of modification, the 
results were inconsistent with the expected values, leading us to believe that the concentrations 
of amine groups present were too high for the TNBS test to handle, leading to absorbance values 
that were inverse or inconsistent.  
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Absorbance (nm) 
Tube Designation Test 1 (λ=325nm) Test 2 (λ=420nm) Test 3 (λ=420nm) 
Blank (1) 0.329 0.004 0.001 
Blank (2) 0.341 0.574 0.93 
LMW (1) 0.571 N/A N/A 
LMW (2) 0.551 N/A N/A 
HMW (1) 0.606 1.208 1.216 
HMW (2) 0.598 1.231 1.204 
Modified LMW (1) 0.553 N/A N/A 
Modified LMW (2) 0.563 N/A N/A 
Modified HMW (1) 0.606 1.269 1.248 
Modified HMW (2) 0.612 1.297 1.285 
 
                           Table 2:  Results of TNBS Testing on Procedures 1, 2, and 3 
  
This inconsistency in results from TNBS testing led us to attempt confirmation of 
modification using High Performance Liquid Chromatography.  Chromatograms were taken of 
each attempt at synthesis both before and after purification using YM100 membrane 
concentrators.  The first set of HPLC spectra showed a set of peaks that confirmed some degree 
of modification, but were consistent with an incomplete modification due to an overabundance of 
polylysine.  The second set of HPLC spectra were inconclusive and showed an extremely noisy 
and impure signal consistent with an overabundance of unmodified polylysine and free MPEG-
Imidazolide.  The third set of HPLC spectra showed a clean peak that is consistent with the 
literature value for modified polylysine, and showed only very small traces of free MPEG-
Imidazolide.  These spectra only improved after further purification was attempted. 
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Stabilization Testing 
After successful synthesis of the different molecular weights of PGC, the PGCs were adhered to 
citrate stabilized gold nanoparticles.  This led to the testing and subsequent analysis of MPEG-
gPLL coated GNPs to determine the optimum concentrations for binding and stability.  The first 
cycle of tests involved varying the concentrations of MPEG-gPLL in a constant concentration of 
citrate stabilized GNPs and measuring their absorbance.  This showed a huge spectral shift 
between the concentrations 0.0156 mg/ml and 0.004 mg/ml consistent with successful binding.  
These concentrations were then both increased 10 fold and used for fluorescence spectroscopy.  
This well plate varied the concentrations of citrate stabilized gold nanoparticles while keeping 
the 10 fold increased MPEG-gPLL concentrations constant.  The resulting graph below shows 
fluorescence quenching occurring at an approximate concentration of 0.99 mg/ml of GNPs; this 
again denotes the concentration at which successful binding occurs.  Both concentrations depict 
quenching at this concentration, and have curves of best fit that have a corresponding R-squared 
value of 0.97.  The combined conclusions from these spectra suggest that the optimal 
concentrations for complete MPEG-gPLL and GNP binding occur at the following 
concentrations:  MPEG-gPLL (0.0156 - 0.004 mg/ml) and GNP (0.99 mg/ml). 
 
Analysis of Hydrodynamic Diameter and Zeta Potential Values 
 In order to ascertain the viability of High Molecular Weight vs. Low Molecular Weight 
varieties of the protected graft copolymer for surface coating, our laboratory measured several 
properties of the coated GNPs that were synthesized.  As a preliminary step, the Z average of the 
nanoparticles were measured and found to be nearly identical, due to the preparations involved 
for each being similarly carried out.  Hydrodynamic diameters by number and volume were also 
 29 
 
found to be similar, but hydrodynamic diameter by intensity yielded much different results.  Low 
Molecular Weight MPEG-gPLL coated GNPs showed a nearly 20 nm increase in this case.  The 
intensity distribution of a set of coated nanoparticles is affected greatly by the size of 
subfractions of particles, so it was concluded that the LMW version of our system showed much 
more aggregation in nanoparticles of larger size.  Additionally, the Zeta potential of the LMW 
system showed a larger negative value which corresponds to an inability of the PGC to displace 
the citrate stabilizing the GNPs prior to synthesis of the coated nanoparticles.  HMW populations 
showed only a small positive charge, suggesting that more efficient binding took place for this 
version of the PGC 
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Table 3:   Comparison of Zeta Potential Values and Hydrodynamic Diameter for LMW and 
HMW MPEG-gPLL Coated GNPs 
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Conclusions 
 
 A stable protected graft copolymer was synthesized utilizing both high and low molecular 
weight versions of poly-L-lysine.  The procedure for synthesizing the biocompatible MPEG 
derivative used was determined to be a low-cost, high yield method capable of making a product 
that can be stored in reasonable conditions.  Synthesizing the protected graft copolymer proved 
to be a more complicated procedure, but through several trials and revisions of the procedure, a 
viable product was procured.   
 The stabilization of MPEG-gPLL coated nanoparticles showed that concentrations of 
MPEG-gPLL can vary between 0.0156 mg/ml and 0.004 mg/ml and a concentration of 0.99 
mg/ml of GNPs to promote optimal binding between the PGC and the GNPs.  Measurement of 
the hydrodynamic diameters and Zeta potentials of these coated nanoparticles showed that  
HMW poly-lysine (which resulted in higher mass PGC) provides better stabilization and 
neutralization of GNPs; LMW polymers showed a higher degree of aggregation of resultant 
GNPs, and showed an incomplete displacement of citrate unlike the HMW polylysine based 
PGC.   
 It is my recommendation that further research is undertaken to pursue the incorporation 
of the MPEG-thioacetate into a protected graft copolymer in order to determine whether the 
biocompatible derivative is a factor that contributes to the degree of modification and eventual 
stabilization of the complex.  The MPEG-Imidazolide PGC should also be the focus of further 
testing; changing the synthetic procedure managed to promote better modification of PLL, so it 
could follow that modifying the nanoparticle coating procedure could result in a more desirable 
stabilization for one or both versions of nanoparticle.   
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 After the completion of the above research, the nanoparticles should be stabilization 
tested in conditions mimicking those encountered in the body.  This research was begun during 
my project with the MPEG-Imidazolide PGC, however results were not able to be processed 
before the conclusion of the project.  Investigating this stability would give valuable information 
on how such a drug delivery system could be adapted to target specific tissues and physiological 
conditions to increase overall effectiveness of pharmaceutical treatment. 
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